# Allarity Therapeutics (ALLR) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/ALLR
## Company Profile
- Ticker: ALLR
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Denmark
- Tags: Oncology
## Stock Data
- Close: 1.43 USD
- Market cap: 26889123.56 USD
- Last updated: 2026-08-11
## Business Overview
### Stenoparib-Focused Oncology Company
Allarity Therapeutics is a Phase 2 clinical-stage company developing stenoparib/2X-121, an oral dual inhibitor of PARP1/2 and tankyrase 1/2. The program is focused on advanced ovarian cancer and relapsed small cell lung cancer.
### DRP Companion Diagnostic Strategy
Allarity uses its Drug Response Predictor companion diagnostic to identify patients most likely to benefit from stenoparib. The company has received a Notice of Allowance for a U.S. patent application covering the stenoparib-specific DRP diagnostic.
### Ovarian Cancer Strategy
Stenoparib is advancing in platinum-resistant or platinum-ineligible ovarian cancer under FDA Fast Track designation. The DRP diagnostic is intended to enrich the study population for patients more likely to respond.
### Small Cell Lung Cancer Combination
A VA-funded study is evaluating stenoparib with temozolomide in relapsed small cell lung cancer. This program extends the asset from biomarker-guided monotherapy into a combination-treatment setting.
## Why The Stock Is Moving

As of Aug 11, 2026, ALLR closed up 1.42% at $1.43. No new same-company headline was identified in the current news window.

## Future Catalysts

- A manufacturing campaign for Phase 3-ready stenoparib active pharmaceutical ingredient is expected to be completed in the third quarter of 2026.
- Enrollment has begun in the VA-funded trial of stenoparib plus temozolomide in relapsed SCLC, with future clinical data representing the next program milestone.
- An amended Phase 2 protocol in platinum-resistant or platinum-ineligible ovarian cancer began enrolling in summer 2025, and subsequent data will inform the potential FDA approval path.

## Recent News
- 2026-07-07 12:00 EST — [Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration](https://biopharmsignal.com/news/ALLR/allarity-therapeutics-announces-clia-certification-clearing-the-path-for-advanci-1691650e) — Source: Allarity Therapeutics
- 2026-06-30 12:00 EST — [Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic](https://biopharmsignal.com/news/ALLR/allarity-therapeutics-announces-the-grant-of-essential-u-s-patent-for-its-stenop-de7abd3e) — Source: Allarity Therapeutics
- 2026-06-18 12:00 EST — [Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026](https://biopharmsignal.com/news/ALLR/allarity-therapeutics-to-present-trial-in-progress-poster-on-phase-2-stenoparib--3d7c3404) — Source: Allarity Therapeutics
- 2026-05-15 20:30 EST — [Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers](https://biopharmsignal.com/news/ALLR/allarity-therapeutics-reports-first-quarter-2026-results-and-continued-stenopari-9dd3e261) — Source: Allarity Therapeutics
- 2026-05-08 12:45 EST — [Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm](https://biopharmsignal.com/news/ALLR/allarity-therapeutics-ceo-to-present-at-precision-medicine-forum-europe-2026-in--031409fc) — Source: Allarity Therapeutics